English
Segment disclosures
Company overviewANAPTYSBIO, INC.
Each reported dimension combination stays separate. Revenue and operating income are shown as reported, with their dates and sources.
Revenue · Reported segment facts
4 dimension combinations 25 retained observations 12 reported periods
Counts describe retained dimensioned rows only. Periods and members can change across reports, and this view does not infer missing values or expected segment totals.
Biopharma Company
Statement Business Segments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=anab:BiopharmaCompanyMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-01-01 – 2026-03-31 | 0 | USD | 20260512 | Open filing evidence |
| 2025-01-01 – 2025-12-31 | 0 | USD | 20260303 | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 0 | USD | 20260512 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 0 | USD | 20260303 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 0 | USD | 20260303 | Open filing evidence |
Research And Development Segment
Statement Business Segments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=anab:ResearchAndDevelopmentSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-07-01 – 2025-09-30 | 76320000 | USD | 20251104 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 126354000 | USD | 20251104 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 22263000 | USD | 20250806 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 50034000 | USD | 20250806 | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 27771000 | USD | 20250505 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 91280000 | USD | 20250227 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 30017000 | USD | 20251104 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 48167000 | USD | 20251104 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 10971000 | USD | 20250806 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 18150000 | USD | 20250806 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 7179000 | USD | 20250505 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 17157000 | USD | 20250227 | Open filing evidence |
| 2022-01-01 – 2022-12-31 | 10287000 | USD | 20250227 | Open filing evidence |
Royalty Management Company
Statement Business Segments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=anab:RoyaltyManagementCompanyMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-07-01 – 2026-09-30 | 30274000 | USD | 20261112 | Open filing evidence |
| 2026-01-01 – 2026-03-31 | 25556000 | USD | 20260512 | Open filing evidence |
| 2025-01-01 – 2025-12-31 | 234603000 | USD | 20260303 | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 27771000 | USD | 20260512 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 91280000 | USD | 20260303 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 17157000 | USD | 20260303 | Open filing evidence |
Prior To Spin Off · Royalty Management Company
Statement Operating Activities Segment · Statement Business Segments
Source dimensions
us-gaap:StatementOperatingActivitiesSegmentAxis=anab:PriorToSpinOffMember;us-gaap:StatementBusinessSegmentsAxis=anab:RoyaltyManagementCompanyMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-07-01 – 2025-09-30 | 76320000 | USD | 20261112 | Open filing evidence |